Research Analysts Set Expectations for SGMT Q1 Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT) – Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sagimet Biosciences in a report issued on Thursday, March 13th. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of ($1.00) for the quarter, up from their previous estimate of ($1.08). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Sagimet Biosciences’ Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($1.34) EPS, FY2025 earnings at ($4.86) EPS, FY2026 earnings at ($5.77) EPS, FY2027 earnings at ($5.44) EPS, FY2028 earnings at ($3.74) EPS and FY2029 earnings at ($2.29) EPS.

Separately, Oppenheimer assumed coverage on Sagimet Biosciences in a report on Friday, December 6th. They issued an “outperform” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Sagimet Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Sagimet Biosciences Price Performance

SGMT stock opened at $3.85 on Monday. The business has a 50-day moving average price of $4.18 and a 200 day moving average price of $4.48. The company has a market capitalization of $118.10 million, a P/E ratio of -2.69 and a beta of 2.57. Sagimet Biosciences has a 1-year low of $2.39 and a 1-year high of $7.38.

Sagimet Biosciences (NASDAQ:SGMT) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.15.

Hedge Funds Weigh In On Sagimet Biosciences

A number of large investors have recently added to or reduced their stakes in SGMT. Barclays PLC raised its holdings in Sagimet Biosciences by 14.3% in the third quarter. Barclays PLC now owns 57,230 shares of the company’s stock worth $159,000 after purchasing an additional 7,178 shares in the last quarter. Geode Capital Management LLC raised its holdings in Sagimet Biosciences by 56.7% in the third quarter. Geode Capital Management LLC now owns 252,298 shares of the company’s stock worth $699,000 after purchasing an additional 91,246 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Sagimet Biosciences by 66.2% in the third quarter. JPMorgan Chase & Co. now owns 72,017 shares of the company’s stock worth $199,000 after purchasing an additional 28,690 shares in the last quarter. Jacksonville Wealth Management LLC bought a new position in Sagimet Biosciences in the fourth quarter worth about $45,000. Finally, Stoneridge Investment Partners LLC raised its holdings in Sagimet Biosciences by 22.2% in the fourth quarter. Stoneridge Investment Partners LLC now owns 20,836 shares of the company’s stock worth $94,000 after purchasing an additional 3,780 shares in the last quarter. 87.86% of the stock is currently owned by institutional investors.

Sagimet Biosciences Company Profile

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.